

Amendment to the claims:

Please amend claim 22 and cancel claims 29 and 31 without prejudice.

Listing of Claims:

This listing of claims will replace all prior versions and listings of claims in the Application.

1 (Previously presented). A method for impairing movement of a cutaneous lymphocyte-associated antigen⁺ (CLA⁺) memory T-cell within or to the skin of a mammal, said method comprising administering to said mammal an effective amount of an antibody against cutaneous-T-cell-attracting chemokine (CTACK), whereby administration of said antibody impairs movement of said cutaneous lymphocyte-associated antigen⁺ memory T-cell within or to the skin of said mammal.

2 (Cancelled).

2 ~~3~~ (Previously presented). The method of Claim 1, wherein said movement is within said skin.

3 ~~4~~ (Previously presented). The method of Claim 1, wherein said antibody neutralizes cutaneous-T-cell-attracting chemokine.

Claims 5-21 (Cancelled)

4 ~~22~~ (Currently amended). A method for treating a patient suffering from a skin disorder selected from the group consisting of allergic-contact dermatitis, ~~— and psoriasis, wound healing and carcinoma~~ comprising administering an effective amount of an antibody against cutaneous-T-cell-attracting chemokine.

23 (Cancelled).

5 ~~24~~ (Previously presented). The method of Claim 1, wherein said administering is local.

6 ~~25~~ (Previously presented). The method of Claim 1, wherein said cutaneous lymphocyte-associated antigen⁺ memory T-cell moves into the dermis or epidermis of said skin.

26 (Cancelled).

7 ~~27~~ (Previously presented). The method of Claim ~~27~~⁴~~22~~, wherein said skin disorder is allergic-contact dermatitis.

8 ~~28~~ (Previously presented). The method of Claim ~~28~~⁴~~22~~, wherein said skin disorder is

psoriasis.

29 (Cancelled).

30 (Cancelled).

31 (Cancelled).

32 (Cancelled).

33 (Cancelled).

- 9 ~~34~~ (Previously presented). The method of Claim 1, wherein said administering is systemic.
- 10 ~~35~~ (Previously presented). The method of Claim 1, wherein said administering is topical.
- 11 ~~36~~ (Previously presented). The method of Claim 1, wherein said administering is subcutaneous.
- 12 ~~37~~ (Previously presented). The method of Claim 1, wherein said administering is intradermal.
- 13 ~~38~~ (Previously presented). The method of Claim 1, wherein said administering is transdermal.